Comparative Pharmacology
Head-to-head clinical analysis: XOSPATA versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XOSPATA versus XTANDI.
XOSPATA vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gilteritinib is a tyrosine kinase inhibitor that inhibits FLT3 (FMS-like tyrosine kinase 3) receptor signaling, including FLT3-ITD and FLT3-TKD mutations, leading to apoptosis in leukemic cells.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
120 mg orally once daily.
160 mg orally once daily.
None Documented
None Documented
Terminal half-life 9.1 hours (range 4.4–16.1 hours); supports once-daily dosing.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Fecal (64%) and renal (16%) as metabolites; <1% unchanged in urine.
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic
Antineoplastic